or Try an Advanced Search...

    Technical Analysis for GALT - Galectin Therapeutics Inc.

    Grade Last Price % Change Price Change
    D 2.35 3.98% 0.09
    GALT closed up 3.98 percent on Monday, July 1, 2024, on 69 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Up
    Historical GALT trend table...
    Date Alert Name Type % Chg
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Crossed Above 200 DMA Bullish 0.00%
    NR7 Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    200 DMA Resistance Bearish 3.98%
    Pocket Pivot Bullish Swing Setup 3.98%
    Volume Surge Other 3.98%
    Lower Bollinger Band Walk Weakness 3.98%
    Older End-of-Day Signals for GALT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    Up 3% about 10 hours ago
    Up 2% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GALT Chart by TradingView
    Basic chart:

    Profile

    Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Cancer Alcohol Tumor Melanoma Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Therapies For Cancer Fibrotic Disease Lectins Liver Fibrosis Galectin Lactose Combination Therapy Fatty Liver Fatty Liver Disease Galectin 3 Galecto Biotech

    Is GALT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 7 Galectin Therapeutics: Neutral On Belapectin For NASH Cirrhosis Amid Financial Challenges
    Jun 4 Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
    May 15 Galectin Therapeutics GAAP EPS of -$0.19
    May 15 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
    May 13 Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
    Apr 23 Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
    Apr 9 Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
    Mar 29 Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
    Mar 29 Galectin Therapeutics GAAP EPS of -$0.74
    Mar 29 Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
    See more GALT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.2684
    52 Week Low 1.35
    Average Volume 200,066
    200-Day Moving Average 2.27
    50-Day Moving Average 2.91
    20-Day Moving Average 2.49
    10-Day Moving Average 2.30
    Average True Range 0.21
    RSI (14) 40.48
    ADX 36.67
    +DI 10.28
    -DI 21.23
    Chandelier Exit (Long, 3 ATRs) 2.29
    Chandelier Exit (Short, 3 ATRs) 2.66
    Upper Bollinger Bands 2.90
    Lower Bollinger Band 2.07
    Percent B (%b) 0.33
    BandWidth 33.27
    MACD Line -0.19
    MACD Signal Line -0.18
    MACD Histogram -0.0027
    Fundamentals Value
    Market Cap 145.34 Million
    Num Shares 61.8 Million
    EPS -0.76
    Price-to-Earnings (P/E) Ratio -3.09
    Price-to-Sales 0.00
    Price-to-Book 207.70
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.58
    Resistance 3 (R3) 2.56 2.46 2.54
    Resistance 2 (R2) 2.46 2.40 2.47 2.53
    Resistance 1 (R1) 2.41 2.36 2.43 2.43 2.52
    Pivot Point 2.31 2.31 2.32 2.32 2.31
    Support 1 (S1) 2.25 2.25 2.28 2.27 2.18
    Support 2 (S2) 2.15 2.21 2.16 2.17
    Support 3 (S3) 2.10 2.15 2.16
    Support 4 (S4) 2.12